Ronald Bruce Turner, MD '76, was just announced as the new Chief Medical Officer of G.ST Antivirals (a clinical-stage biotechnology company applying innovative, host cell-based strategies to develop broad-spectrum antivirals against respiratory tract infections). The CEO of G.ST stated, "He is a world leading expert in clinical research of respiratory viruses, whose outstanding work and remarkable contributions to our field I have been following for a long time. His knowledge will be invaluable when driving our clinical development of 2-DG through Phase II and beyond, and I am very much